Therapeutic Adherence in Patients with Chronic Simple Glaucoma
Journal: Advances in Medicine and Engineering Interdisciplinary Research DOI: 10.32629/ameir.v3i2.3817
Abstract
Introduction: Chronic simple glaucoma is one of the leading causes of blindness and visual impairment worldwide and requires ongoing treatment. Therefore, therapeutic adherence is the safest way to control it. Objectives: To determine the level of treatment adherence in patients with chronic simple glaucoma. Methodology: An observational, descriptive, and cross-sectional study was conducted in 44 patients with primary open-angle glaucoma who were seen in the glaucoma clinic of the Bechar Ophthalmological Establishment in Algeria between September and December 2024. Data were obtained through interviews with each patient. The variables analyzed were: age, sex, educational level, prescribed treatment, level of treatment adherence, and reasons for non-adherence. The Morisky-Green-Levine test was used as a measurement instrument. Results: Males and the 60-79 age group were predominant. The most commonly prescribed pharmacological group was prostaglandin analogues. 52.3% of patients used more than one glaucoma medication. Furthermore, 59.1% of patients had poor treatment adherence, with forgetfulness, financial problems, and discomfort caused by the medication being the underlying causes. Conclusion: Treatment adherence in patients with chronic simple glaucoma is low, which exposes them to disease progression, with its associated impact on the individual, family, and society.
Keywords
glaucoma; chronic; treatment; compliance; adherence
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Organización Mundial de la Salud. Ceguera y discapacidad visual. [Internet], 2021. Disponible en: https://www.who.int/es/news-room/factsheets/detail/blindness-and-visualimpairment
[2] Barría von Bischhoffshause F, Jiménez Román J. Guía latinoamericana de glaucoma primario de ángulo abierto para el médico oftalmólogo general. México, DF: Consejo Internacional de Oftalmología; 2019. Disponible en: https://paao.org/wp-content/uploads/2016/05/Guia-Glaucoma-2019-final-parawww.pdf
[3] Flores Sanchez BC, Tatham AJ. Acute angle closure glaucoma. Br J Hosp Med. 2019; 80(12). Disponible en: https://www.magonlinelibrary.com/doi/abs/10.12968/hmed.2019.80.12.C174
[4] Romero Chía A.D.Glaucoma: un reto para la salud pública. [Internet]. 2020. Disponible en: http://repositorio.uan.edu.co/bitstream/123456789/2342/1/2020AnaDanielaRomeroChia.pdf
[5] Schuster A, Erb C, Hoffmann E, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. [Internet]. 2020. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196841
[6] Pérez-González H., Hernández-Silva J, Tamargo-Barbeito T. Extracción precoz del cristalino para el control de la presión intraocular en cierre angular primario. Anales de la Academia de Ciencias de Cuba. [Internet]. 2023;13(2). Disponible en: https://revistaccuba.sld.cu/index.php/revacc/article/view/1274
[7] Jacobs DS. Open-angle glaucoma: Epidemiology, clinical presentation and diagnosis. Uptodate. 2022 Sep. Disponible en: https://www.uptodate.com/contents/open-angle-glaucoma-epidemiology-clinicalpresentation-and-diagnosis
[8] Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11): 2081-90. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0161642014004333
[9] World Health Organization. Adherence to long-term therapies: evidence for action. 2003. Disponible en: https://www.who.int/chp/knowledge/publications/adherence_introduction.pdf?ua=1
[10] Adherencia al tratamiento .Resumen de campana de adherencia al tratamiento 2022. Disponible en: https://asociaciondeglaucoma.es/el-glaucoma/adherencia-al-tratamiento/
[11] Barris Blundell D. Adherencia al tratamiento del glaucoma en pacientes de una farmacia comunitaria. Pharm Care Esp [Internet]. 23 de octubre de 2012;14(5): 202. Disponible en: https://www.pharmcareesp.com/index.php/PharmaCARE/article/view/90
[12] Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherent. Med Care. 1986;24: 67-74.
[13] Dilla T, Valladares A, Lizán L, et al. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora [Internet]. Elsevier. 2009;41(6). Disponible en: https://www.elsevier.es/es-revista-atencion-primaria-27-articulo adherencia-persistencia-terapeutica-causas-consecuencias-S0212656709001504
[14] He S, Stankowska DL, Ellis DZ, Krishnamurthy RR, Yorio T. Targets of Neuroprotection in Glaucoma. J Ocul Pharmacol Ther [Internet]. 2018 Jan/Feb; 34(1-2): 85-106. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963639
[15] Movahedinejad T, Adib-hajbaghery M. Adherence to treatment in patients with open-angle glaucoma and its related factors. Electron Physician [Internet]. 2016 Sep 20;8(9): 2954-61. Disponible en: http://www.ephysician.ir/index.php/browse-issues/2016/9/467-2954
[16] Omoti AE Omoti AE, Ukponmwan CU. Cumplimiento con los nuevos medicamentos antiglaucoma en Benin City (Nigeria). Seguim Farmacoter. 2005;3(3): 135-143.
[17] Dreer L, Girkin C, Mansberger S. Determinants of medication adherence to topical glaucoma therapy. J Glaucoma [Internet]. 2012 Apr-May;21(4): 234-40. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183317
[18] Rivas Gallardo, W., Lorca Valenzuela, A, & Rivera Munizaga, L. (2023). Estudio de adherencia al tratamiento antiglaucomatoso y factores asociados en pacientes del Centro de la Visión como basepara generar una herramienta digital. Revista Confluencia, 6(1): 23-27. https://revistas.udd.cl/index.php/confluencia/article/view/865
[19] Pomares AJ, Vázquez MA, Ruíz ES. Adherencia terapéutica en pacientes con hipertensión arterial. Finlay [Internet]. 2017;7(2): [aprox. 7p.]. Disponible en: https://www.revfinlay.sld.cu/index.php/finlay/article/view/47612
[20] López SA, Chávez R. Adherencia al tratamiento antihipertensivo en pacientes mayores de 60 años. Rev Haban Cienc Méd [Internet]. 2016;15(1): [aprox 5p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X20160001000069
[21] Paula Anne Newman-Casey, Taylor Blachley, Paul P. Lee, Michele Heisler, Karen B. Farris, Joshua D. Stein. Patterns of glaucoma medication adherence over four years of follow-up, ophthalmology. 2015;122(10): 2010-2021. Disponible en: https://doi.org/10.1016/j.ophtha.2015.06.039
[2] Barría von Bischhoffshause F, Jiménez Román J. Guía latinoamericana de glaucoma primario de ángulo abierto para el médico oftalmólogo general. México, DF: Consejo Internacional de Oftalmología; 2019. Disponible en: https://paao.org/wp-content/uploads/2016/05/Guia-Glaucoma-2019-final-parawww.pdf
[3] Flores Sanchez BC, Tatham AJ. Acute angle closure glaucoma. Br J Hosp Med. 2019; 80(12). Disponible en: https://www.magonlinelibrary.com/doi/abs/10.12968/hmed.2019.80.12.C174
[4] Romero Chía A.D.Glaucoma: un reto para la salud pública. [Internet]. 2020. Disponible en: http://repositorio.uan.edu.co/bitstream/123456789/2342/1/2020AnaDanielaRomeroChia.pdf
[5] Schuster A, Erb C, Hoffmann E, Dietlein T, Pfeiffer N. The diagnosis and treatment of glaucoma. [Internet]. 2020. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196841
[6] Pérez-González H., Hernández-Silva J, Tamargo-Barbeito T. Extracción precoz del cristalino para el control de la presión intraocular en cierre angular primario. Anales de la Academia de Ciencias de Cuba. [Internet]. 2023;13(2). Disponible en: https://revistaccuba.sld.cu/index.php/revacc/article/view/1274
[7] Jacobs DS. Open-angle glaucoma: Epidemiology, clinical presentation and diagnosis. Uptodate. 2022 Sep. Disponible en: https://www.uptodate.com/contents/open-angle-glaucoma-epidemiology-clinicalpresentation-and-diagnosis
[8] Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11): 2081-90. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0161642014004333
[9] World Health Organization. Adherence to long-term therapies: evidence for action. 2003. Disponible en: https://www.who.int/chp/knowledge/publications/adherence_introduction.pdf?ua=1
[10] Adherencia al tratamiento .Resumen de campana de adherencia al tratamiento 2022. Disponible en: https://asociaciondeglaucoma.es/el-glaucoma/adherencia-al-tratamiento/
[11] Barris Blundell D. Adherencia al tratamiento del glaucoma en pacientes de una farmacia comunitaria. Pharm Care Esp [Internet]. 23 de octubre de 2012;14(5): 202. Disponible en: https://www.pharmcareesp.com/index.php/PharmaCARE/article/view/90
[12] Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherent. Med Care. 1986;24: 67-74.
[13] Dilla T, Valladares A, Lizán L, et al. Adherencia y persistencia terapéutica: causas, consecuencias y estrategias de mejora [Internet]. Elsevier. 2009;41(6). Disponible en: https://www.elsevier.es/es-revista-atencion-primaria-27-articulo adherencia-persistencia-terapeutica-causas-consecuencias-S0212656709001504
[14] He S, Stankowska DL, Ellis DZ, Krishnamurthy RR, Yorio T. Targets of Neuroprotection in Glaucoma. J Ocul Pharmacol Ther [Internet]. 2018 Jan/Feb; 34(1-2): 85-106. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963639
[15] Movahedinejad T, Adib-hajbaghery M. Adherence to treatment in patients with open-angle glaucoma and its related factors. Electron Physician [Internet]. 2016 Sep 20;8(9): 2954-61. Disponible en: http://www.ephysician.ir/index.php/browse-issues/2016/9/467-2954
[16] Omoti AE Omoti AE, Ukponmwan CU. Cumplimiento con los nuevos medicamentos antiglaucoma en Benin City (Nigeria). Seguim Farmacoter. 2005;3(3): 135-143.
[17] Dreer L, Girkin C, Mansberger S. Determinants of medication adherence to topical glaucoma therapy. J Glaucoma [Internet]. 2012 Apr-May;21(4): 234-40. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3183317
[18] Rivas Gallardo, W., Lorca Valenzuela, A, & Rivera Munizaga, L. (2023). Estudio de adherencia al tratamiento antiglaucomatoso y factores asociados en pacientes del Centro de la Visión como basepara generar una herramienta digital. Revista Confluencia, 6(1): 23-27. https://revistas.udd.cl/index.php/confluencia/article/view/865
[19] Pomares AJ, Vázquez MA, Ruíz ES. Adherencia terapéutica en pacientes con hipertensión arterial. Finlay [Internet]. 2017;7(2): [aprox. 7p.]. Disponible en: https://www.revfinlay.sld.cu/index.php/finlay/article/view/47612
[20] López SA, Chávez R. Adherencia al tratamiento antihipertensivo en pacientes mayores de 60 años. Rev Haban Cienc Méd [Internet]. 2016;15(1): [aprox 5p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X20160001000069
[21] Paula Anne Newman-Casey, Taylor Blachley, Paul P. Lee, Michele Heisler, Karen B. Farris, Joshua D. Stein. Patterns of glaucoma medication adherence over four years of follow-up, ophthalmology. 2015;122(10): 2010-2021. Disponible en: https://doi.org/10.1016/j.ophtha.2015.06.039
Copyright © 2025 Yargelis González Orza, Yaima Hodelin Romero, Yamile Sánchez Carbonell, Idael Sánchez Hechavarria, Tania Yelina Silva Chil
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
